Evidence map›Paper›PMID 40227960›Full record

Trial reportAnesthesiology2025

Impact of Point-of-care Allogeneic Red Blood Cell Washing on Markers of Transfusion-related Respiratory Complications: A Phase II Randomized Clinical Trial.

Daryl J Kor, Matthew A Warner, Philip J Norris, Sarah Armour, Erica D Wittwer, Paula J Santrach, Laurie A Meade, Chelsea M Conn, Phillip J Schulte, Richard S Pendegraft and 3 more

Abstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
In one paragraph

Trial report in Anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Daryl J KorDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-9110-1648
Matthew A WarnerDivision of Critical Care, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.
Philip J NorrisVitalant Research Institute, San Francisco, California; Departments of Pathology and Laboratory Medicine, University of California-San Francisco, San Francisco, California.
Sarah ArmourDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.
Erica D WittwerDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.
Paula J SantrachDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Laurie A MeadeDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.
Chelsea M ConnDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Phillip J SchulteDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Richard S PendegraftDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Clara Di GermanioImmunology Core, Vitalant Research Institute, San Francisco, California; Laboratory Medicine, University of California-San Francisco, San Francisco, California.
Mihai PodgoreanuDepartment of Anesthesiology, Duke University Medical Center, Raleigh, North Carolina.
Ian J WelsbyDuke University Medical Center, Durham, North Carolina.

Funding

Institutional Career Development CoreKL2TR002379 · NCATS · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2017 to 2026
$14.9M
Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary ComplicationsR01HL121232 · NHLBI · MAYO CLINIC ROCHESTER · PI KOR, DARYL J, WELSBY, IAN J · 2014 to 2018
$3.2M
Attenuation of Anemia for the Optimization of Post-Hospitalization Functional Recovery in Survivors of Critical IllnessK23HL153310 · NHLBI · MAYO CLINIC ROCHESTER · PI WARNER, MATTHEW A · 2021 to 2025
$909k
NCATS NIH HHS KL2 TR002379NHLBI NIH HHS K23 HL153310NHLBI NIH HHS R01 HL121232
6 · The paper itself

Abstract

backgroundTransfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) are leading causes of transfusion-related morbidity and mortality. Soluble factors in erythrocyte supernatant may increase risk for these complications. The authors hypothesized that point-of-care allogeneic erythrocyte washing may be an effective intervention to mitigate elevations in soluble factors as well as physiologic responses associated with transfusion-associated respiratory complications in the setting of cardiac surgery.

methodsThis is a two-center, nonblinded, randomized clinical trial evaluating point-of-care washed versus standard issue allogeneic erythrocyte transfusions administered during or on the day of cardiac surgery. The primary analysis was performed via modified intention to treat. The primary outcomes assessed were changes in intermediate markers of lung injury as well as cardiopulmonary physiologic responses to erythrocyte transfusion. Secondary outcomes included the duration of intensive care unit and hospital stay, durations of mechanical ventilation and oxygen supplementation, presence of TRALI or TACO, and mortality.

resultsAmong 154 analyzed patients (81 washed, 73 standard issue), the median age was 66 yr, and 77 (50.0%) were women. The median (interquartile range) number of allogeneic erythrocyte units transfused on the day of surgery was 3.0 (2.0 to 5.0) in the washed erythrocyte group and 3.0 (2.0 to 4.0) in the standard issue group ( P = 0.13). No between-group differences were identified in any of the assessed recipient lung injury biomarkers (all P values > adjusted alpha). Durations of intensive care unit stay (median [interquartile range], 3.0 [2.0 to 5.0] vs. 3.0 [2.0 to 4.0] days; P = 0.117) and hospital length of stay (12.0 [9.0 to 17.0] vs. 12.0 [9.0 to 17.0] days; P = 0.801) were similar, as were the number of ventilator-free days at day 28 (27.0 [27.0 to 27.0] vs. 27.0 [26.0 to 27.0]; P = 0.699) and oxygen-free days at day 28 (24.0 [19.0 to 26.0] vs. 24.0 [22.0 to 26.0]; P = 0.400). No significant differences were noted in mortality rate or in incidence rates for TRALI, TACO, and acute kidney injury.

conclusionsAmong patients undergoing cardiovascular surgery with high risk of erythrocyte transfusion, point-of-care washing of allogeneic erythrocyte transfusions did not mitigate changes in intermediate markers of lung injury or cardiopulmonary physiologic responses to erythrocyte transfusion and was not associated with improved clinical outcomes.

Indexed as

ErythrocytesErythrocyte TransfusionPoint-of-Care SystemsTransfusion-Related Acute Lung InjuryAgedBiomarkersFemaleHumansMaleMiddle AgedBiomarkers

Identifiers

PMID40227960
PMCPMC12151772

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.